Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Calcium gluconate

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Calcium Gluconate (ca Gluc) (opens in a new tab)Original source URL: https://globalrph.com/dilution/calcium-gluconate-ca-gluc/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/calcium-gluconate-ca-gluc/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:44:37.133564+00:00
Source location
div.post-content
Packaged content SHA-256
035c2d601b03d53c1a2a58ee313baca048661a0ae6284867db5ac1a4f75b63c4
Original response SHA-256
d7b76762eb9a00127c03e56966fc1b13edbe7d4f6d15940620cf46b7e2f04470
Source body SHA-256
9c4b5609969062febfee0b33af4f32784e795e3d2d378c20d399b4579a72a3dc

CALCIUM GLUCONATE

The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents

D5W, NS Calcium chloride link

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]

[1 to 4 grams] [50 - 100 ml] [See comments]*

Alternatively:
[1 gram ] [50 ml ] [1 hour ^]
[2 grams ] [100 ml ] [2 hours ^]

*Dilutions assume peripheral line is used as well as D5W as the primary diluent (see comment section below - calculation of solution osmolarity).

^Actual infusion times should be based on serial calcium levels, severity of the deficit, current phosphate level (possible metastatic calcification), and the clinical presentation of the patient (acute versus chronic; symptoms present; etc.).

Treatment of emergent (acute symptomatic) patient. 1.

[The injection should be halted if the patient complains of any discomfort; it may be resumed when symptoms disappear. Following injection, the patient should remain recumbent for a short time. 2]

Calcium Gluconate: Maximum rate: 1.5 mL/minute = 0.7 meq/minute. 3

See monograph for general dosing.

Smaller volumes may be used in patients with a central line. Actual infusion rates should be based on the severity of the deficit. In non-emergent cases (asymptomatic patients), oral therapy is preferred.

-Serum calcium levels should be measured every 2 to 6 hours to guide continued therapy. If the patient has a low serum albumin level, ionized calcium should be monitored.

-The following patients need continuous ECG monitoring during calcium infusions: (1) Patient's with cardiac arrhythmias or (2) Patients receiving digoxin therapy.

Continuous infusion: Initially multiply ( 0.5 x Wt (kg) X 24 ) / 93 mg = number of grams of calcium gluconate needed. Add calculated amount to 500 to 1000 ml D5W or NS. A continuous infusion may be used in symptomatic patients with hypocalcemia. Infusion rate: 0.3 to 2 mg/kg/hr based on elemental calcium. The actual rate should be based on serial plasma calcium levels.

Comments / Stability / Miscellaneous

1 gram= 4.65 meq (93 mg) 10 ml.

"Hypocalcemia is defined as a serum calcium concentration <8.5 mg/dL (or ionized calcium <4.2 mg/dL). Symptoms of hypocalcemia usually occur when ionized levels fall to <2.5 mg/dL. Symptoms include paresthesias of the extremities and face, followed by muscle cramps, carpopedal spasm, stridor, tetany, and seizures. Hypocalcemic patients show hyperreflexia and positive Chvostek and Trousseau signs. Cardiac effects include decreased myocardial contractility and heart failure." [Source].

Treatment of ACUTE SYMPTOMATIC hypocalcemia, maximum rates, etc:

Return to article top

Asymptomatic patients should be treated with oral calcium.
For additional information see the following page:
https://globalrph.com/drugs/calcium-supplements/


"Hypocalcemia is defined as a serum calcium concentration <8.5 mg/dL (or ionized calcium <4.2 mg/dL). Hypocalcemia may develop with toxic shock syndrome, with abnormalities in serum magnesium, after thyroid surgery, with fluoride poisoning, and with tumor lysis syndrome (rapid cell turnover with resultant hyperkalemia, hyperphosphatemia, and hypocalcemia). Symptoms of hypocalcemia usually occur when ionized levels fall to <2.5 mg/dL. Symptoms include paresthesias of the extremities and face, followed by muscle cramps, carpopedal spasm, stridor, tetany, and seizures. Hypocalcemic patients show hyperreflexia and positive Chvostek and Trousseau signs. Cardiac effects include decreased myocardial contractility and heart failure. Hypocalcemia can exacerbate digitalis toxicity.". 1.

Intravenous calcium should be restricted to acute symptomatic patients that require prompt therapy.

"Treatment of Hypocalcemia: Treatment of hypocalcemia requires administration of calcium.
Treat acute, symptomatic hypocalcemia with 10% calcium gluconate, 93 to 186 mg of elemental calcium (10 to 20 mL) IV over 10 minutes. Follow this with an IV infusion of 540 to 720 mg of elemental calcium (58 to 77 mL of 10% calcium gluconate) in 500 to 1000 mL D5W at 0.5 to 2 mg/kg per hour (10 to 15 mg/kg)". 1.

"Alternatively, administer 10% calcium chloride, giving 5 mL (136.5 mg of elemental calcium) over 10 minutes, followed by 36.6 mL (1 g) over the next 6 to 12 hours IV. Measure serum calcium every 4 to 6 hours. Aim to maintain the total serum calcium concentration at 7 to 9 mg/dL. Correct abnormalities in magnesium, potassium, and pH simultaneously. Note that untreated hypomagnesemia will often make hypocalcemia refractory to therapy. Therefore, evaluate serum magnesium when hypocalcemia is present and particularly if hypocalcemia is refractory to initial calcium therapy." 1.

Maximum rates, equivalents, etc:
Calcium Chloride: Maximum rate: 1.0 mL/minute = 1.36 meq/minute. 2
Calcium Gluconate: Maximum rate: 1.5 mL/minute = 0.7 meq/minute. 3
Trissel: Maximum rate (calcium injections): 0.7 to 1.8 mEq/minute. 4

Calcium Conversions:

Calcium Chloride 1 gram (10ml)
= 273 mg elemental calcium
= 13.6 mEq
= 6.8 mmol.
20mg of elemental calcium per mEq.
0.5 mmol of elemental calcium = 1.0 mEq.
Calcium Gluconate 1 gram (10ml)
= 93 mg elemental calcium
= 4.65 mEq
= 2.325 mmol.
20mg of elemental calcium per mEq.
0.5 mmol of elemental calcium = 1.0 mEq.
Example conversion: 0.075 mmol elemental calcium/kg/hr = 0.15 mEq/kg/hr = 3 mg/kg/hr.

Osmolarity calculations:

Return to article top source: https://globalrph.com/medcalcs/osmolarity-calculator-extremely-powerful-tool/

Osmolarity calculations: source: https://globalrph.com/medcalcs/osmolarity-calculator-extremely-powerful-tool/
Example: 3 grams added to 50 ml D5W:
The total volume of the final solution is: 80.0 ml, and the total milliosmoles in solution is 33.0 mOsm and the calculated osmolarity of the final solution is 412 mOsm/Liter. The osmolarity is between 280 mOsm/L and 500 mOsm/L ...... No problems anticipated. Normal plasma osmolarity: 280-310 mOsm/L. Cephalic and basilic veins in the upper arms can usually be used as long as the final pH is above 5 and under 9.


Maximum IV rate: 1.5 ml/min or approximately 1 gram/ 7 minutes.

Too rapid injection may decrease blood pressure or cause cardiac syncope. Calcium administration: (Onset: rapid Duration: 30min to 2 hours. ).

Recommended only in cases of hyperkalemia, hypocalcemia, or calcium antagonist blockade.

--------------------------------------------------------------------------------

Treatment of hypocalcemia: Acute hypocalcemic tetany (unless induced by alkalosis): give 1 gram calcium gluconate IV over 5 - 15 minutes. After 1-2 hours may be necessary to repeat dose or add 2-3 grams calcium gluconate to 250-500ml and infuse over 12-24hours.

----Alternatively----
Symptomatic patient: give 1 gram calcium gluconate over 5 - 15 minutes q1-2hours. If Tetany returns after 6 hours (3 grams calcium gluconate given) start continuous infusion [5-10g of calcium gluconate /1000 ml D5W infused at rate to prevent tetany-usually 30 to 100 ml/hr]. Make sure magnesium levels are corrected first - patients with hypocalcemia and hypomagnesemia will not respond to calcium replacement. Alternative therapy: give 0.3 to 2 mg elemental calcium/kg/hour as a continuous infusion.

Asymptomatic patient: 1 gram calcium gluconate IV q6-12h with careful monitoring of Ca++ levels. Monitoring: during intensive therapy, monitor calcium levels at least twice daily.

--------------------------------------------------------------------------------

Differentiation of hypoparathyroidism vs Vitamin D deficiency:
Hypoparathyroidism: Decreased serum Ca++/serum PO4 increased/Alk phos normal.
Vitamin D deficiency: decreased Ca++ & PO4/ Alk phos increased.

Drug Monograph - Calcium gluconate

Return to article top

DRUG DESCRIPTION
Calcium Gluconate is the calcium salt of gluconic acid, an oxidation product of glucose, and contains 9.3% calcium, which is about one-third of the calcium in strength of calcium chloride USP. Since it is soluble to the extent of only one part in 30 parts of cold water, the 10% solution is supersaturated and is stabilized by the addition of calcium saccharate tetrahydrate 0.46% w/v (which supplies calcium 6.2%). Each mL contains 98 mg of calcium gluconatemonohydrate, 4.6 mg of calcium saccharate tetrahydrate, and Water for Injection USP, q.s. Each mL provides 9.3 mg (0.465 milliequivalents) of calcium.

INDICATIONS
Calcium gluconate is used to treat conditions arising from calcium deficiencies such as hypocalcemic tetany, hypocalcemia related to hypoparathyrodism and hypocalcemia due to rapid growth or pregnancy. It is also used in the treatment of black widow spider bites to relieve muscle cramping and as an adjunct in the treatment of rickets, osteomalacia, lead colic and magnesium sulfate overdosage. Calcium gluconate has also been employed to decrease capillary permeability in allergic conditions, nonthrombocytopenic purpura and exudative dermatoses such as dermatitis herpetiformis and for pruritus of eruptions caused by certain drugs. In hyperkalemia, calcium gluconate may aid in antagonizing the cardiac toxicity provided the patient is not receiving digitalis therapy.

Precautions
General

To avoid undesirable reactions that may follow rapid intravenous administration of calcium gluconate, the drug should be given slowly, e.g., approximately 1.5 mL over a period of one minute. When injected intravenously, calcium gulconate should be injected through a small needle into a large vein in order to avoid too rapid an increase in serum calcium and extravasation of calcium solution into the surrounding tissue with resultant necrosis.

Rapid injection of calcium gluconate may cause vasodilation, decreased blood pressure, bardycardia, cardiac arrhythmias, syncope and cardiac arrest.

Because of the danger involved in simultaneous use of calcium salts and drugs of the digitalis group, a digitalized patient should not receive an intravenous injection of a calcium compound unless indications are clearly defined.

Drug Interactions
The inotropic and toxic effects of cardiac glycosides and calcium are synergistic, and arrhythmias may occur if these drugs are given together (particularly when calcium is given together particularly when calcium is given intravenously). Intravenous administration of calcium should be avoided in patients receiving cardiac glycosides; if necessary, calcium should be given slowly in small amounts.

Calcium complexes tetracycline antibiotics rendering them inactive. The two drugs should not be given at the same time orally nor should they be mixed for parenteral administration.

Calcium gluconate injection has been reported to be incompatible with intravenous solutions containing various drugs. Published data are too varied and/or limited to permit generalizations, and specialized reference should be consulted for specific information.

Adverse Reactions
Patients may complain of tingling sensations, a sense of oppression or heat waves and a calcium or chalky taste following the intravenous administration of calcium gluconate.

Rapid intravenous injection of calcium salts may cause vasodilation, decreased blood pressure, bardycardia, cardiac arrhythmias, syncope and cardiac arrest. Use in digitalized patients may precipitate arrhythmias.

Local necrosis and abscess formation may occur with intramuscular injection.

DOSAGE AND ADMINISTRATION
Calcium Gluconate should be administered intravenously either directly or by infusion. The dose is dependent upon the individual requirements of the patient. Calcium Gluconate may also be administered by intermittent infusion at a rate not exceeding 200 mg/min, or by continuous infusion.

Usual Dosage
Adults: 500 mg - 2 grams (5-20 mL)

Children: 200-500 mg (2-5 mL)

Infants: not more than 200 mg (not more than 2 mL)

HOW SUPPLIED
Calcium Gluconate Injection, USP 10%

NDC 0517-3910-25 10% 10 mL Single Dose Vials packed in boxes of 25
NDC 0517-3950-25 10% 50 mL Single Dose Vials packed in boxes of 25
NDC 0517-3900-25 10% 100 mL Pharmacy Bulk Package packed in boxes of 25

Supersaturated solutions are prone to precipitation.

NOTE: If crystallization has occurred, warming in a 60°C water bath for 15-30 minutes with occasional shaking, may dissolve the precipitate. Cool to body temperature before use. The injection must be clear at the time of use. Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit.

No preservative added. Unused portion of vial should be discarded. Use only if solution is clear and seal intact.

Store at controlled room temperature 15º- 30ºC (59º- 86ºF) (See USP).

References: Return to article top

[1 ] 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 10.1: Life-Threatening Electrolyte Abnormalities. Circulation. 2005;112:IV-121-IV-125. Accessed - revisited: 05/01/11.
https://circ.ahajournals.org/cgi/content/full/112/24_suppl/IV-121

[2 ] CALCIUM CHLORIDE injection, solution (10% Calcium Chloride) [Hospira, Inc.] Hospira, Inc., Lake Forest, IL 60045 USA. Revised: November,
2009. [Package Insert: accessed: 05/01/11]

[3 ] CALCIUM GLUCONATE injection, solution (10% CALCIUM GLUCONATE). APP Pharmaceuticals, LLC. Schaumburg, IL 60173. Revised:
February 2009. [Package Insert: accessed: 05/01/11]

[4 ] Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:245-6.

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
monitor_or_titrate
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      calcium-gluconate
      Source IDH51-3A305A9ED9CE3227633E45AA
      Generic name
      Calcium gluconate
      Source IDH51-A6B682C9FBEBF4F4D16AF656
      Class
      Electrolytes and fluids
      Source IDH51-528E3CE6EB4AB0BC759A5E92
      Subclass
      Calcium replacement
      Source IDH51-B336C84EEC81AB6B7E51148F
      Primary uses
      1. Hypocalcemia
        Source IDH51-15A7DA97D9610B798D65C067
      2. Hyperkalemia with ECG changes
        Source IDH51-363938626FC01E70EA255CC0
      3. Calcium-channel blocker toxicity
        Source IDH51-AD95CF9175CDBDE69444EB7B
      Mechanism
      Supplies ionized calcium for membrane excitability, contraction, coagulation, and signaling.
      Source IDH51-FD4E25B94EBF047770CDD872
      Mechanism level
      drug_specific
      Source IDH51-11D9BA5EE15FFDA5C878D82F
      Basic dosing orientation
      Adult | Existing preparation record; use current package insert for indication-specific selection | Common dose 1 to 2 g of 10% solution | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Pediatric and neonatal | Existing preparation record; use current package insert for indication-specific selection | Weight-based dose | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion
      Source IDH51-71BE40FEB968F8B181962237
      Administration orientation
      Infuse over 10 to 60 minutes depending on urgency and dose; Slow monitored administration; 100 mg/mL or diluted; Usually over approximately 10 minutes while perfusing
      Source IDH51-7CAD93A8254D18DAE9B3DB2D
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal function materially affects toxicity, monitoring, or titration even when a fixed table may not apply.
      Source IDH51-8B14B55F017469153989EA30
      Key safety orientation
      1. Do not mix with bicarbonate or phosphate solutions.
        Source IDH51-3580864E16FB0D14109AB853
      2. Extravasation can still cause injury.
        Source IDH51-F3AB8EA0D75BF5FFD05A7C98
      3. Use caution with digoxin toxicity.
        Source IDH51-1C61A1C1081F29FEBA10FF3F
      Coverage path
      structured_local_snapshot
      Source IDH51-BA42AF6917DF4D3E9059AA57
      Coverage path label
      Structured GlobalRPh route snapshot
      Source IDH51-0E4A17169D7FAE3B168DCF4E
      Legacy title
      Calcium gluconate
      Source IDH51-6E0C550FCD57FAED7806CDDB
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-0579C62220ACC80BAB01ECC7
      Search text
      Calcium gluconate Electrolytes and fluids Calcium replacement Hypocalcemia Hyperkalemia with ECG changes Calcium-channel blocker toxicity Supplies ionized calcium for membrane excitability, contraction, coagulation, and signaling. Adult | Existing preparation record; use current package insert for indication-specific selection | Common dose 1 to 2 g of 10% solution | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Pediatric and neonatal | Existing preparation record; use current package insert for indication-specific selection | Weight-based dose | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion Infuse over 10 to 60 minutes depending on urgency and dose; Slow monitored administration; 100 mg/mL or diluted; Usually over approximately 10 minutes while perfusing Renal function materially affects toxicity, monitoring, or titration even when a fixed table may not apply. Do not mix with bicarbonate or phosphate solutions. Extravasation can still cause injury. Use caution with digoxin toxicity. Structured GlobalRPh route snapshot
      Source IDH51-A96D5AA933DB577CC769F22B
      Official access mode
      search
      Source IDH51-E65AF12ADC139FCC63FFEC5B
      Official search query
      Calcium gluconate
      Source IDH51-4A3C37830387524DA5AA3B0B
      Official access reason
      A source-backed DailyMed search is available; select and confirm the exact IV product.
      Source IDH51-2E139A751E58F87716D26956

      No separate structured rows were bundled for continuous infusion, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical dilution and intermittent infusion preparation

      Recovered v5.1 source content; historical, awaiting current review.

      PopulationAmountReconstitutionDiluentFinal volumeConcentrationRateStabilityNotes
      Source IDH51-752B67A443626F5C1F2893D0
      Adult
      Source IDH51-FB053CE2D2711FD3DE2CE205
      Common dose 1 to 2 g of 10% solution
      Source IDH51-889B5CDD7C4D4F6A4263BC46
      Usually supplied as 100 mg/mL solution.
      Source IDH51-89C81ADFD16C45A2CB4B065E
      NS or D5W
      Source IDH51-AFEDE88CC768A0DA6262B435
      50 to 100 mL for routine replacement
      Source IDH51-DC3BF63EB795AD688A077E37
      Commonly 10 to 20 mg/mL
      Source IDH51-68447324E43F8A031AE4CCAC
      Infuse over 10 to 60 minutes depending on urgency and dose
      Source IDH51-B5CFE20F3FAD5BB0F023D13F
      Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.
      Source IDH51-E6D2F4B78564B93B9F6CCA75
      For emergent membrane stabilization, a slow injection/short infusion may be used with ECG monitoring.
      Source IDH51-B30A5E439AAF55D99E33A849
      Source IDH51-1B5C940C0267389EC03299AE
      Pediatric and neonatal
      Source IDH51-2C20C18B2EA9D6F0ED2BCFC1
      Weight-based dose
      Source IDH51-CB53A0DEE0224B976AC7DE3D
      Use pharmacy-prepared dilution.
      Source IDH51-199D2A8CB4EFB145E7527DC7
      Compatible fluid
      Source IDH51-95DBA33F8765BE5B215940D1
      Weight-appropriate volume
      Source IDH51-6FEA4EADA8DCB1B5C5BB1663
      Protocol-specific
      Source IDH51-1498FD4AB0548478C21C60C2
      Slow monitored administration
      Source IDH51-BE0E5485E342FF715917DB89
      Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.
      Source IDH51-83D2E3C56E644D009AC1A403

      Historical IV-push guidance

      Recovered v5.1 source content; historical, awaiting current review.

      PopulationDose scopeConcentrationRateStatusNotes
      Source IDH51-56211A897F6175595A2394F0
      Adult emergency
      Source IDH51-A2AB302526AE79C33C1EAC44
      Commonly 1 g of 10% solution
      Source IDH51-684F93347BD818D8D4BAE993
      100 mg/mL or diluted
      Source IDH51-E9CABD6F8284690C76507FB1
      Usually over approximately 10 minutes while perfusing
      Source IDH51-86FCB0FDFB87FDE1A94BFA2C
      Slow IV injection/short infusion; not a rapid push
      Source IDH51-ED6EB375EA8FD96866C8005B
      Confirm line patency and monitor ECG.
      Source IDH51-9C1BD6D1338553106622EE8E

      Historical indication and population dosing

      Recovered tables and source-separated snapshots; full clinical revalidation remains pending.

      Existing dose and route snapshots

      RoutePopulationIndicationDoseIntervalDurationAdministrationSource levelNotes
      Source IDH51-D16D18944A0473283DF011CF
      IV infusion
      Source IDH51-D226F3C585313B94337057B6
      Adult
      Source IDH51-BFEFDA5E51F413357EBB18E5
      Existing preparation record; use current package insert for indication-specific selection
      Source IDH51-2A5FA07D25FD68D74C553FF8
      Common dose 1 to 2 g of 10% solution
      Source IDH51-9BBB03B67199EF800FEEDA77
      Not normalized in the preparation record
      Source IDH51-FFD5CA9FDF7CB88D372F5EF7
      See current package insert and professional guidance
      Source IDH51-111D0032481D85C4454AD5F1
      Infuse over 10 to 60 minutes depending on urgency and dose
      Source IDH51-B23C10D340A46A0C808346DE
      Existing GlobalRPh structured preparation snapshot
      Source IDH51-DAAC23FBBB8BB4D5B335499C
      For emergent membrane stabilization, a slow injection/short infusion may be used with ECG monitoring.
      Source IDH51-AED54F0BCCD41BF77CE46248
      Source IDH51-39322B30B56D14E3B877CA6D
      IV infusion
      Source IDH51-33BB04B913CCB4625C524181
      Pediatric and neonatal
      Source IDH51-4DD2ABE38F2AD2F2E87FAA03
      Existing preparation record; use current package insert for indication-specific selection
      Source IDH51-12903A53641A5154ABB3676C
      Weight-based dose
      Source IDH51-50F303815513C856A3D62CF6
      Not normalized in the preparation record
      Source IDH51-7F50993576AC5C73501BACD9
      See current package insert and professional guidance
      Source IDH51-594CD14D75B68A158F1B1D35
      Slow monitored administration
      Source IDH51-D07048378CFD245F8B8AC0F6
      Existing GlobalRPh structured preparation snapshot
      Source IDH51-A7C53403A8D3348C0C1AFF9C
      Source IDH51-8DD153F9710F0F5459BBDBAF
      IV push
      Source IDH51-C5C9E73A4CDA4DA1BD3F3626
      Adult emergency
      Source IDH51-69EBB4D296621642E518C983
      Commonly 1 g of 10% solution
      Source IDH51-D00ABF74FC2E18CB59FEAAB3
      Commonly 1 g of 10% solution
      Source IDH51-BB1F4EBD3654D4E3C0C3FB8F
      Patient- and indication-specific
      Source IDH51-10CA5B94042DA1C4B338CF9A
      See current package insert
      Source IDH51-ED5872DAF1571A648B7BFA14
      Usually over approximately 10 minutes while perfusing
      Source IDH51-19319F212AF56EBD3E01C899
      Existing GlobalRPh IV push snapshot
      Source IDH51-1A159382BF5DF9FA22A986DA
      Slow IV injection/short infusion; not a rapid push Confirm line patency and monitor ECG.
      Source IDH51-34433989BB37032D64630286

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      monitor_or_titrate
      Source IDH51-80295CBD8DB0B71177C9C1F4
      Summary
      Renal function materially affects toxicity, monitoring, or titration even when a fixed table may not apply.
      Source IDH51-E0757F1AD49037951B277605
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-145E2C382E1240CD559E5657

      Historical Common IV uses

      Recovered v5.1 source content; historical, awaiting current review.

      1. Hypocalcemia
        Source IDH51-77AE02271CB27C17B26F7636
      2. Hyperkalemia with ECG changes
        Source IDH51-A011BABB2CDCC47F184A063C
      3. Calcium-channel blocker toxicity
        Source IDH51-D80D84BB2E4A714260201937

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Do not mix with bicarbonate or phosphate solutions.
        Source IDH51-C6F97FB0A8B425F614A5ACB2
      2. Extravasation can still cause injury.
        Source IDH51-7DF0509F448ADB346365032C
      3. Use caution with digoxin toxicity.
        Source IDH51-33DF67AB9D27C846EC1E2E4E

      Historical Monitoring

      Recovered v5.1 source content; historical, awaiting current review.

      1. ECG during urgent use
        Source IDH51-CC776726D281464802774F75
      2. Ionized calcium
        Source IDH51-0391EC0E76F629FAB5B255B2
      3. IV site
        Source IDH51-78E8C82F667891C85988356C
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      calcium-gluconate
      Source IDH51-0B77ECC74E372B57D2FBB52A
      Generic name
      Calcium gluconate
      Source IDH51-48B08E783B3AD11B100FB11C
      Aliases
      1. calcium gluconate 10%
        Source IDH51-BC4FCCE1208D4B7FE3E9A889
      Class
      Electrolytes and fluids
      Source IDH51-E6403603B2263FE3F4EAFCE9
      Subclass
      Calcium replacement
      Source IDH51-7D34DAD141E33F03B2C27D42
      Summary
      Calcium salt preferred over calcium chloride for many peripheral-line applications because it is less damaging with extravasation, though tissue injury remains possible.
      Source IDH51-6392D4669FC38CCF1486F5B6
      Populations
      1. Adult
        Source IDH51-F37C69EB8F0D09FB6FA37A85
      2. Pediatric
        Source IDH51-2ED26A74649ACDFE55F142EE
      3. Neonatal
        Source IDH51-1BE9EDB8F81B9714A0BB7C3D
      Evidence tier
      Core reference - verify current label
      Source IDH51-408EA05070B62DFC375057EA
      High alert
      true
      Source IDH51-56AD66CC621E0435B88541F7
      Hazardous
      false
      Source IDH51-956C05544B70C2B87371D78E
      Status
      Active
      Source IDH51-C04BD3EC5D5CE1835B0FD0DD
      Reviewed
      2026-08-29
      Source IDH51-77ED9671210F377BD0AE599A
      Version added
      1.0
      Source IDH51-DCDC54FEED1A23F45821F4E7
      Sources
      LabelUrlKind
      Source IDH51-8C80BC209741B2F7B48AAA76
      DailyMed label search
      Source IDH51-4A09E65B652D30BB93D1B224
      https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Calcium+gluconate (opens in a new tab)
      Source IDH51-090CE9128FB54869479219A2
      Primary
      Source IDH51-E080DA56F9A475D2114D724B
      Source IDH51-9B67F57C6C7DC26F8FE74D54
      GlobalRPh legacy IV dilution monograph
      Source IDH51-F779ECA3B7EA975211C6A1C6
      legacy:auto
      Source IDH51-3441FAC0162FDD252839FA6C
      Legacy
      Source IDH51-2DEE110BAD82BBEF578B088C
      Legacy title
      Calcium gluconate
      Source IDH51-88E6F85A1812C6CD67D8955C
      Clinical release verification
      Audit version
      3.4
      Source IDH51-F45D3A9AF3527588F1C6F79E
      Audited on
      2026-08-30
      Source IDH51-0EA52D6757C7FEB6A29D4DA7
      Level
      amber
      Source IDH51-FD7B1CCD90BA29989555A07C
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-F3A228011B2BF3771B26D31B
      Exact current label candidate
      false
      Source IDH51-2C6034ADE4FB4F8288AE0297
      Numeric support ratio
      0
      Source IDH51-DA7C5199C7EF86826EC3D152
      Reference url count
      1
      Source IDH51-FF82925AC1AD5A897C552813
      Broken reference count
      0
      Source IDH51-4C130F591829E1ABA02B7ACD
      Point of use confirmation required
      true
      Source IDH51-6109B997542FD4091EF91202
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-21DFFC60C6E68E37C1B1AF9A

      Dosing source fields

      Id
      calcium-gluconate
      Source IDH51-A14FA62D301FDF7F85628302
      Generic name
      Calcium gluconate
      Source IDH51-A80E228DDB1615CFFC7341E0
      Coverage status
      direct_official_label_access_plus_local_snapshot
      Source IDH51-6047E08441EB1D323FB0A9F4
      Package insert
      Query name
      Calcium gluconate
      Source IDH51-C0559CFAB506B157B0CF9438
      Product and route must match
      true
      Source IDH51-FC2D27CC5CC6CBE7E81AFB97
      Live current label enabled
      false
      Source IDH51-E69C0BA69F87571D446918F1
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-DAB51DFC9F2B1CF977E920FB
      Direct official label access enabled
      true
      Source IDH51-9F1D5B213295E4BE63213CE1
      Outbound server request required
      false
      Source IDH51-BD177F68190F078347ADB5CD
      Local summary status
      not_bundled
      Source IDH51-3889BA59A2FE414F19CD8625
      Clinical review
      Locally normalized
      false
      Source IDH51-F00F4F9342B333C8205D157D
      Reviewed
      2026-08-29
      Source IDH51-B45E3B681F1D844A6D713DDA
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-0833FCA96AD8A32733E7A4B7
      Clinical release verification
      Audit version
      3.4
      Source IDH51-EB3BF3D45D9445C5AEFACA62
      Audited on
      2026-08-30
      Source IDH51-DEA1D330112A59B200988F4B
      Level
      amber
      Source IDH51-C2768677F3BD1DB5AF782F2E
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-13BE96245CD89FEF242A5F91
      Exact current label candidate
      false
      Source IDH51-A5A08EFFCAD84A1B5C048D34
      Numeric support ratio
      0
      Source IDH51-DB6B462027FDFA45D35FE47E
      Reference url count
      1
      Source IDH51-564E3C39EA8C78D1D283FFE8
      Broken reference count
      0
      Source IDH51-EC72A0D0407B46AE519317DE
      Point of use confirmation required
      true
      Source IDH51-9A2B271465216358D8DA3D86
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-11B5FBC14EAB4067C33FED76
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      calcium-gluconate
      Source IDH51-7ED0A95A1A8A5B4D43180586
      Name
      Calcium gluconate
      Source IDH51-FE9CEA581072F4D9DE2797BF
      Therapeutic class
      Electrolytes and fluids
      Source IDH51-EF816155BCBD6E942033974A
      Review version
      3.1
      Source IDH51-6DE640D9BCBA27C4ECDA7362
      Review date
      2026-08-30
      Source IDH51-D14E1C2C595C02F0B671467A
      Release status
      structured_record_current_label_not_confirmed
      Source IDH51-983060D5CDD80592661938CE
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-0E771D27DCA28A67F8819CA0
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-E330D75FF801AC855197FC9F
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-E150FE7A669E60B3F382CB78
      Reconstitution concentration
      Usually supplied as 100 mg/mL solution. Use pharmacy-prepared dilution.
      Source IDH51-5BB8D91569ABCA81E6D683BE
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-217BD563C95AE9DCEF949A81
      Appropriate standardized containers
      50 to 100 mL for routine replacement Weight-appropriate volume
      Source IDH51-69A659EC76AA76DE376BF63B
      Adult dosing range
      Common dose 1 to 2 g of 10% solution Weight-based dose Commonly 1 g of 10% solution Commonly 1 g of 10% solution
      Source IDH51-35885E8746B1E68FAD91542E
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-E6D76E118AA9CD295C7BA550
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-E52C7097F54414A9C147CFAE
      Infusion time
      Infuse over 10 to 60 minutes depending on urgency and dose Slow monitored administration Usually over approximately 10 minutes while perfusing
      Source IDH51-8A44C6A47F6596C483C7B33C
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-B844D5315DFB3ED14A113D8A
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-4D8C02342D44D4909E7544A6
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-51A4DF615CCC067980F964F5
      Reconstitution concentration
      Primary
      existing_structured_record
      Source IDH51-7A16E69CECF1E1D12218D3D9
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-348E0B841C480157251DF235
      Appropriate standardized containers
      Primary
      existing_structured_record
      Source IDH51-BC64B58154F02B3CA79E8EFF
      Adult dosing range
      Primary
      existing_structured_record
      Source IDH51-B1C5CD7457E22D3767C2E297
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-565EAF2F24BD97E93DEEBD3E
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-651F923DBC1F8582238CB5A4
      Infusion time
      Primary
      existing_structured_record
      Source IDH51-DD795E37BA3ABB47715D2871
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-2F439C8E19E40249ADE580EA
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-3CDBF84C2804263DDE986DF0
      Population applicability
      Adult
      Applicability
      supported_or_source_present
      Source IDH51-D5187CDEA7B80F0A8996E807
      Guide generation allowed
      true
      Source IDH51-D6F1F01AC9666C49FE0C9DB0
      Pediatric
      Applicability
      supported_or_source_present
      Source IDH51-9EFB0611BEE5A687016CDDA4
      Guide generation allowed
      false
      Source IDH51-EA4105CE41CBDD7843B79513
      Neonatal
      Applicability
      supported_or_source_present
      Source IDH51-502CA456B44DBC27FB55E3D9
      Guide generation allowed
      false
      Source IDH51-51D05898C900C99D628D2030
      Route presence
      Structured dilution
      true
      Source IDH51-D3812B8730B9A2839D345130
      Iv push
      true
      Source IDH51-D3220CB10B739AF5E74A2F39
      Continuous infusion
      true
      Source IDH51-1C7A65BD5EA7BED0134515F4
      Pediatric source
      true
      Source IDH51-5FC26B6C6CAA6BE809DAD4FC
      Neonatal source
      true
      Source IDH51-4BDDAE3DA7590D9DADD0E3BF
      Legacy reference
      Status
      not_available
      Source IDH51-7BD77A44C9AD934AEB5F1321
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-D6159B380B0F81B68A686E05
      Source files
      1. catalog.json
        Source IDH51-A79A7D6C7417F66116A64921
      2. dosing.json
        Source IDH51-B1B21B40C065C3EB26BC928D
      3. legacy-map.json
        Source IDH51-DA264B90EA2978D822BF37AA
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-06B817B18691490AFE4FB85B
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-0B77ECC74E372B57D2FBB52Acatalog.json
      /records/38/id
      Historical; current review incomplete
      H51-48B08E783B3AD11B100FB11Ccatalog.json
      /records/38/generic_name
      Historical; current review incomplete
      H51-BC4FCCE1208D4B7FE3E9A889catalog.json
      /records/38/aliases/0
      Historical; current review incomplete
      H51-E6403603B2263FE3F4EAFCE9catalog.json
      /records/38/class
      Historical; current review incomplete
      H51-7D34DAD141E33F03B2C27D42catalog.json
      /records/38/subclass
      Historical; current review incomplete
      H51-6392D4669FC38CCF1486F5B6catalog.json
      /records/38/summary
      Historical; current review incomplete
      H51-77AE02271CB27C17B26F7636catalog.json
      /records/38/common_uses/0
      Historical; current review incomplete
      H51-A011BABB2CDCC47F184A063Ccatalog.json
      /records/38/common_uses/1
      Historical; current review incomplete
      H51-D80D84BB2E4A714260201937catalog.json
      /records/38/common_uses/2
      Historical; current review incomplete
      H51-752B67A443626F5C1F2893D0catalog.json
      /records/38/preparations/0
      Historical; current review incomplete
      H51-FB053CE2D2711FD3DE2CE205catalog.json
      /records/38/preparations/0/population
      Historical; current review incomplete
      H51-889B5CDD7C4D4F6A4263BC46catalog.json
      /records/38/preparations/0/amount
      Historical; current review incomplete
      H51-89C81ADFD16C45A2CB4B065Ecatalog.json
      /records/38/preparations/0/reconstitution
      Historical; current review incomplete
      H51-AFEDE88CC768A0DA6262B435catalog.json
      /records/38/preparations/0/diluent
      Historical; current review incomplete
      H51-DC3BF63EB795AD688A077E37catalog.json
      /records/38/preparations/0/final_volume
      Historical; current review incomplete
      H51-68447324E43F8A031AE4CCACcatalog.json
      /records/38/preparations/0/concentration
      Historical; current review incomplete
      H51-B5CFE20F3FAD5BB0F023D13Fcatalog.json
      /records/38/preparations/0/rate
      Historical; current review incomplete
      H51-E6D2F4B78564B93B9F6CCA75catalog.json
      /records/38/preparations/0/stability
      Historical; current review incomplete
      H51-B30A5E439AAF55D99E33A849catalog.json
      /records/38/preparations/0/notes
      Historical; current review incomplete
      H51-1B5C940C0267389EC03299AEcatalog.json
      /records/38/preparations/1
      Historical; current review incomplete
      H51-2C20C18B2EA9D6F0ED2BCFC1catalog.json
      /records/38/preparations/1/population
      Historical; current review incomplete
      H51-CB53A0DEE0224B976AC7DE3Dcatalog.json
      /records/38/preparations/1/amount
      Historical; current review incomplete
      H51-199D2A8CB4EFB145E7527DC7catalog.json
      /records/38/preparations/1/reconstitution
      Historical; current review incomplete
      H51-95DBA33F8765BE5B215940D1catalog.json
      /records/38/preparations/1/diluent
      Historical; current review incomplete
      H51-6FEA4EADA8DCB1B5C5BB1663catalog.json
      /records/38/preparations/1/final_volume
      Historical; current review incomplete
      H51-1498FD4AB0548478C21C60C2catalog.json
      /records/38/preparations/1/concentration
      Historical; current review incomplete
      H51-BE0E5485E342FF715917DB89catalog.json
      /records/38/preparations/1/rate
      Historical; current review incomplete
      H51-83D2E3C56E644D009AC1A403catalog.json
      /records/38/preparations/1/stability
      Historical; current review incomplete
      H51-7CFC206AD25C101A3EEFE023catalog.json
      /records/38/preparations/1/notes
      Historical; current review incomplete
      H51-56211A897F6175595A2394F0catalog.json
      /records/38/iv_push/0
      Historical; current review incomplete
      H51-A2AB302526AE79C33C1EAC44catalog.json
      /records/38/iv_push/0/population
      Historical; current review incomplete
      H51-684F93347BD818D8D4BAE993catalog.json
      /records/38/iv_push/0/dose_scope
      Historical; current review incomplete
      H51-E9CABD6F8284690C76507FB1catalog.json
      /records/38/iv_push/0/concentration
      Historical; current review incomplete
      H51-86FCB0FDFB87FDE1A94BFA2Ccatalog.json
      /records/38/iv_push/0/rate
      Historical; current review incomplete
      H51-ED6EB375EA8FD96866C8005Bcatalog.json
      /records/38/iv_push/0/status
      Historical; current review incomplete
      H51-9C1BD6D1338553106622EE8Ecatalog.json
      /records/38/iv_push/0/notes
      Historical; current review incomplete
      H51-C6F97FB0A8B425F614A5ACB2catalog.json
      /records/38/warnings/0
      Historical; current review incomplete
      H51-7DF0509F448ADB346365032Ccatalog.json
      /records/38/warnings/1
      Historical; current review incomplete
      H51-33DF67AB9D27C846EC1E2E4Ecatalog.json
      /records/38/warnings/2
      Historical; current review incomplete
      H51-CC776726D281464802774F75catalog.json
      /records/38/monitoring/0
      Historical; current review incomplete
      H51-0391EC0E76F629FAB5B255B2catalog.json
      /records/38/monitoring/1
      Historical; current review incomplete
      H51-78E8C82F667891C85988356Ccatalog.json
      /records/38/monitoring/2
      Historical; current review incomplete
      H51-F37C69EB8F0D09FB6FA37A85catalog.json
      /records/38/populations/0
      Historical; current review incomplete
      H51-2ED26A74649ACDFE55F142EEcatalog.json
      /records/38/populations/1
      Historical; current review incomplete
      H51-1BE9EDB8F81B9714A0BB7C3Dcatalog.json
      /records/38/populations/2
      Historical; current review incomplete
      H51-408EA05070B62DFC375057EAcatalog.json
      /records/38/evidence_tier
      Historical; current review incomplete
      H51-56AD66CC621E0435B88541F7catalog.json
      /records/38/high_alert
      Historical; current review incomplete
      H51-956C05544B70C2B87371D78Ecatalog.json
      /records/38/hazardous
      Historical; current review incomplete
      H51-C04BD3EC5D5CE1835B0FD0DDcatalog.json
      /records/38/status
      Historical; current review incomplete
      H51-77ED9671210F377BD0AE599Acatalog.json
      /records/38/reviewed
      Historical; current review incomplete
      H51-DCDC54FEED1A23F45821F4E7catalog.json
      /records/38/version_added
      Historical; current review incomplete
      H51-8C80BC209741B2F7B48AAA76catalog.json
      /records/38/sources/0
      Historical; current review incomplete
      H51-4A09E65B652D30BB93D1B224catalog.json
      /records/38/sources/0/label
      Historical; current review incomplete
      H51-090CE9128FB54869479219A2catalog.json
      /records/38/sources/0/url
      Historical; current review incomplete
      H51-E080DA56F9A475D2114D724Bcatalog.json
      /records/38/sources/0/kind
      Historical; current review incomplete
      H51-9B67F57C6C7DC26F8FE74D54catalog.json
      /records/38/sources/1
      Historical; current review incomplete
      H51-F779ECA3B7EA975211C6A1C6catalog.json
      /records/38/sources/1/label
      Historical; current review incomplete
      H51-3441FAC0162FDD252839FA6Ccatalog.json
      /records/38/sources/1/url
      Historical; current review incomplete
      H51-2DEE110BAD82BBEF578B088Ccatalog.json
      /records/38/sources/1/kind
      Historical; current review incomplete
      H51-88E6F85A1812C6CD67D8955Ccatalog.json
      /records/38/legacy_title
      Historical; current review incomplete
      H51-F45D3A9AF3527588F1C6F79Ecatalog.json
      /records/38/clinical_release_verification/audit_version
      Historical; current review incomplete
      H51-0EA52D6757C7FEB6A29D4DA7catalog.json
      /records/38/clinical_release_verification/audited_on
      Historical; current review incomplete
      H51-FD7B1CCD90BA29989555A07Ccatalog.json
      /records/38/clinical_release_verification/level
      Historical; current review incomplete
      H51-F3A228011B2BF3771B26D31Bcatalog.json
      /records/38/clinical_release_verification/release_gate
      Historical; current review incomplete
      H51-2C6034ADE4FB4F8288AE0297catalog.json
      /records/38/clinical_release_verification/exact_current_label_candidate
      Historical; current review incomplete
      H51-A4CD526D2B37CB7CBB9E7DCCcatalog.json
      /records/38/clinical_release_verification/selected_setid
      Historical; current review incomplete
      H51-4EB25468BFFBB19DB4D27C1Fcatalog.json
      /records/38/clinical_release_verification/selected_label_title
      Historical; current review incomplete
      H51-DA7C5199C7EF86826EC3D152catalog.json
      /records/38/clinical_release_verification/numeric_support_ratio
      Historical; current review incomplete
      H51-FF82925AC1AD5A897C552813catalog.json
      /records/38/clinical_release_verification/reference_url_count
      Historical; current review incomplete
      H51-4C130F591829E1ABA02B7ACDcatalog.json
      /records/38/clinical_release_verification/broken_reference_count
      Historical; current review incomplete
      H51-6109B997542FD4091EF91202catalog.json
      /records/38/clinical_release_verification/point_of_use_confirmation_required
      Historical; current review incomplete
      H51-21DFFC60C6E68E37C1B1AF9Acatalog.json
      /records/38/clinical_release_verification/note
      Historical; current review incomplete
      H51-B0D86F81A86BFE1A08AB9119catalog.json
      /records/38/clinical_release_verification/dailymed_search_url
      Historical; current review incomplete
      H51-A14FA62D301FDF7F85628302dosing.json
      /records/38/id
      Historical; current review incomplete
      H51-A80E228DDB1615CFFC7341E0dosing.json
      /records/38/generic_name
      Historical; current review incomplete
      H51-6047E08441EB1D323FB0A9F4dosing.json
      /records/38/coverage_status
      Historical; current review incomplete
      H51-C0559CFAB506B157B0CF9438dosing.json
      /records/38/package_insert/query_name
      Historical; current review incomplete
      H51-1C704691DB434AC2439FC3FBdosing.json
      /records/38/package_insert/preferred_setid
      Historical; current review incomplete
      H51-FC2D27CC5CC6CBE7E81AFB97dosing.json
      /records/38/package_insert/product_and_route_must_match
      Historical; current review incomplete
      H51-E69C0BA69F87571D446918F1dosing.json
      /records/38/package_insert/live_current_label_enabled
      Historical; current review incomplete
      H51-DAB51DFC9F2B1CF977E920FBdosing.json
      /records/38/package_insert/source_priority
      Historical; current review incomplete
      H51-9F1D5B213295E4BE63213CE1dosing.json
      /records/38/package_insert/direct_official_label_access_enabled
      Historical; current review incomplete
      H51-BD177F68190F078347ADB5CDdosing.json
      /records/38/package_insert/outbound_server_request_required
      Historical; current review incomplete
      H51-3889BA59A2FE414F19CD8625dosing.json
      /records/38/package_insert/local_summary_status
      Historical; current review incomplete
      H51-80295CBD8DB0B71177C9C1F4dosing.json
      /records/38/renal/classification
      Historical; current review incomplete
      H51-E0757F1AD49037951B277605dosing.json
      /records/38/renal/summary
      Historical; current review incomplete
      H51-145E2C382E1240CD559E5657dosing.json
      /records/38/renal/method_note
      Historical; current review incomplete
      H51-D16D18944A0473283DF011CFdosing.json
      /records/38/existing_route_snapshots/0
      Historical; current review incomplete
      H51-D226F3C585313B94337057B6dosing.json
      /records/38/existing_route_snapshots/0/route
      Historical; current review incomplete
      H51-BFEFDA5E51F413357EBB18E5dosing.json
      /records/38/existing_route_snapshots/0/population
      Historical; current review incomplete
      H51-2A5FA07D25FD68D74C553FF8dosing.json
      /records/38/existing_route_snapshots/0/indication
      Historical; current review incomplete
      H51-9BBB03B67199EF800FEEDA77dosing.json
      /records/38/existing_route_snapshots/0/dose
      Historical; current review incomplete
      H51-FFD5CA9FDF7CB88D372F5EF7dosing.json
      /records/38/existing_route_snapshots/0/interval
      Historical; current review incomplete
      H51-111D0032481D85C4454AD5F1dosing.json
      /records/38/existing_route_snapshots/0/duration
      Historical; current review incomplete
      H51-B23C10D340A46A0C808346DEdosing.json
      /records/38/existing_route_snapshots/0/administration
      Historical; current review incomplete
      H51-DAAC23FBBB8BB4D5B335499Cdosing.json
      /records/38/existing_route_snapshots/0/source_level
      Historical; current review incomplete
      H51-AED54F0BCCD41BF77CE46248dosing.json
      /records/38/existing_route_snapshots/0/notes
      Historical; current review incomplete
      H51-39322B30B56D14E3B877CA6Ddosing.json
      /records/38/existing_route_snapshots/1
      Historical; current review incomplete
      H51-33BB04B913CCB4625C524181dosing.json
      /records/38/existing_route_snapshots/1/route
      Historical; current review incomplete
      H51-4DD2ABE38F2AD2F2E87FAA03dosing.json
      /records/38/existing_route_snapshots/1/population
      Historical; current review incomplete
      H51-12903A53641A5154ABB3676Cdosing.json
      /records/38/existing_route_snapshots/1/indication
      Historical; current review incomplete
      H51-50F303815513C856A3D62CF6dosing.json
      /records/38/existing_route_snapshots/1/dose
      Historical; current review incomplete
      H51-7F50993576AC5C73501BACD9dosing.json
      /records/38/existing_route_snapshots/1/interval
      Historical; current review incomplete
      H51-594CD14D75B68A158F1B1D35dosing.json
      /records/38/existing_route_snapshots/1/duration
      Historical; current review incomplete
      H51-D07048378CFD245F8B8AC0F6dosing.json
      /records/38/existing_route_snapshots/1/administration
      Historical; current review incomplete
      H51-A7C53403A8D3348C0C1AFF9Cdosing.json
      /records/38/existing_route_snapshots/1/source_level
      Historical; current review incomplete
      H51-B63C6032EC5E5F9E2EFC3136dosing.json
      /records/38/existing_route_snapshots/1/notes
      Historical; current review incomplete
      H51-8DD153F9710F0F5459BBDBAFdosing.json
      /records/38/existing_route_snapshots/2
      Historical; current review incomplete
      H51-C5C9E73A4CDA4DA1BD3F3626dosing.json
      /records/38/existing_route_snapshots/2/route
      Historical; current review incomplete
      H51-69EBB4D296621642E518C983dosing.json
      /records/38/existing_route_snapshots/2/population
      Historical; current review incomplete
      H51-D00ABF74FC2E18CB59FEAAB3dosing.json
      /records/38/existing_route_snapshots/2/indication
      Historical; current review incomplete
      H51-BB1F4EBD3654D4E3C0C3FB8Fdosing.json
      /records/38/existing_route_snapshots/2/dose
      Historical; current review incomplete
      H51-10CA5B94042DA1C4B338CF9Adosing.json
      /records/38/existing_route_snapshots/2/interval
      Historical; current review incomplete
      H51-ED5872DAF1571A648B7BFA14dosing.json
      /records/38/existing_route_snapshots/2/duration
      Historical; current review incomplete
      H51-19319F212AF56EBD3E01C899dosing.json
      /records/38/existing_route_snapshots/2/administration
      Historical; current review incomplete
      H51-1A159382BF5DF9FA22A986DAdosing.json
      /records/38/existing_route_snapshots/2/source_level
      Historical; current review incomplete
      H51-34433989BB37032D64630286dosing.json
      /records/38/existing_route_snapshots/2/notes
      Historical; current review incomplete
      H51-F00F4F9342B333C8205D157Ddosing.json
      /records/38/clinical_review/locally_normalized
      Historical; current review incomplete
      H51-B45E3B681F1D844A6D713DDAdosing.json
      /records/38/clinical_review/reviewed
      Historical; current review incomplete
      H51-0833FCA96AD8A32733E7A4B7dosing.json
      /records/38/clinical_review/status
      Historical; current review incomplete
      H51-EB3BF3D45D9445C5AEFACA62dosing.json
      /records/38/clinical_release_verification/audit_version
      Historical; current review incomplete
      H51-DEA1D330112A59B200988F4Bdosing.json
      /records/38/clinical_release_verification/audited_on
      Historical; current review incomplete
      H51-C2768677F3BD1DB5AF782F2Edosing.json
      /records/38/clinical_release_verification/level
      Historical; current review incomplete
      H51-13BE96245CD89FEF242A5F91dosing.json
      /records/38/clinical_release_verification/release_gate
      Historical; current review incomplete
      H51-A5A08EFFCAD84A1B5C048D34dosing.json
      /records/38/clinical_release_verification/exact_current_label_candidate
      Historical; current review incomplete
      H51-74ADCC3A5E3560BC2C898ECEdosing.json
      /records/38/clinical_release_verification/selected_setid
      Historical; current review incomplete
      H51-5E3486CF36C8471D893C9C5Cdosing.json
      /records/38/clinical_release_verification/selected_label_title
      Historical; current review incomplete
      H51-DB6B462027FDFA45D35FE47Edosing.json
      /records/38/clinical_release_verification/numeric_support_ratio
      Historical; current review incomplete
      H51-564E3C39EA8C78D1D283FFE8dosing.json
      /records/38/clinical_release_verification/reference_url_count
      Historical; current review incomplete
      H51-EC72A0D0407B46AE519317DEdosing.json
      /records/38/clinical_release_verification/broken_reference_count
      Historical; current review incomplete
      H51-9A2B271465216358D8DA3D86dosing.json
      /records/38/clinical_release_verification/point_of_use_confirmation_required
      Historical; current review incomplete
      H51-11B5FBC14EAB4067C33FED76dosing.json
      /records/38/clinical_release_verification/note
      Historical; current review incomplete
      H51-E0FB0CE3CBD911BCB1644F1Ddosing.json
      /records/38/clinical_release_verification/dailymed_search_url
      Historical; current review incomplete
      H51-3A305A9ED9CE3227633E45AAfirst-look-v5.1.json
      /records/38/id
      Historical; current review incomplete
      H51-A6B682C9FBEBF4F4D16AF656first-look-v5.1.json
      /records/38/generic_name
      Historical; current review incomplete
      H51-528E3CE6EB4AB0BC759A5E92first-look-v5.1.json
      /records/38/class
      Historical; current review incomplete
      H51-B336C84EEC81AB6B7E51148Ffirst-look-v5.1.json
      /records/38/subclass
      Historical; current review incomplete
      H51-15A7DA97D9610B798D65C067first-look-v5.1.json
      /records/38/primary_uses/0
      Historical; current review incomplete
      H51-363938626FC01E70EA255CC0first-look-v5.1.json
      /records/38/primary_uses/1
      Historical; current review incomplete
      H51-AD95CF9175CDBDE69444EB7Bfirst-look-v5.1.json
      /records/38/primary_uses/2
      Historical; current review incomplete
      H51-FD4E25B94EBF047770CDD872first-look-v5.1.json
      /records/38/mechanism
      Historical; current review incomplete
      H51-11D9BA5EE15FFDA5C878D82Ffirst-look-v5.1.json
      /records/38/mechanism_level
      Historical; current review incomplete
      H51-71BE40FEB968F8B181962237first-look-v5.1.json
      /records/38/basic_dosing_orientation
      Historical; current review incomplete
      H51-7CAD93A8254D18DAE9B3DB2Dfirst-look-v5.1.json
      /records/38/administration_orientation
      Historical; current review incomplete
      H51-8B14B55F017469153989EA30first-look-v5.1.json
      /records/38/renal_and_population_orientation
      Historical; current review incomplete
      H51-3580864E16FB0D14109AB853first-look-v5.1.json
      /records/38/key_safety_orientation/0
      Historical; current review incomplete
      H51-F3AB8EA0D75BF5FFD05A7C98first-look-v5.1.json
      /records/38/key_safety_orientation/1
      Historical; current review incomplete
      H51-1C61A1C1081F29FEBA10FF3Ffirst-look-v5.1.json
      /records/38/key_safety_orientation/2
      Historical; current review incomplete
      H51-BA42AF6917DF4D3E9059AA57first-look-v5.1.json
      /records/38/coverage_path
      Historical; current review incomplete
      H51-0E4A17169D7FAE3B168DCF4Efirst-look-v5.1.json
      /records/38/coverage_path_label
      Historical; current review incomplete
      H51-2647F031556ED4527F41C7DCfirst-look-v5.1.json
      /records/38/official_label_url
      Historical; current review incomplete
      H51-6E0C550FCD57FAED7806CDDBfirst-look-v5.1.json
      /records/38/legacy_title
      Historical; current review incomplete
      H51-0579C62220ACC80BAB01ECC7first-look-v5.1.json
      /records/38/review_note
      Historical; current review incomplete
      H51-A96D5AA933DB577CC769F22Bfirst-look-v5.1.json
      /records/38/search_text
      Historical; current review incomplete
      H51-D2A988BCE82934A449055C13first-look-v5.1.json
      /records/38/official_search_url
      Historical; current review incomplete
      H51-E65AF12ADC139FCC63FFEC5Bfirst-look-v5.1.json
      /records/38/official_access_mode
      Historical; current review incomplete
      H51-9AFA308CE86D023F004BFCA8first-look-v5.1.json
      /records/38/official_access_url
      Historical; current review incomplete
      H51-4A3C37830387524DA5AA3B0Bfirst-look-v5.1.json
      /records/38/official_search_query
      Historical; current review incomplete
      H51-2E139A751E58F87716D26956first-look-v5.1.json
      /records/38/official_access_reason
      Historical; current review incomplete
      H51-7ED0A95A1A8A5B4D43180586preparation-assessments-v3.8.json
      /38/id
      Historical; current review incomplete
      H51-FE9CEA581072F4D9DE2797BFpreparation-assessments-v3.8.json
      /38/name
      Historical; current review incomplete
      H51-4A8C6B16F21FDE2F95876E20preparation-assessments-v3.8.json
      /38/brands
      Historical; current review incomplete
      H51-EF816155BCBD6E942033974Apreparation-assessments-v3.8.json
      /38/therapeutic_class
      Historical; current review incomplete
      H51-6DE640D9BCBA27C4ECDA7362preparation-assessments-v3.8.json
      /38/review_version
      Historical; current review incomplete
      H51-D14E1C2C595C02F0B671467Apreparation-assessments-v3.8.json
      /38/review_date
      Historical; current review incomplete
      H51-983060D5CDD80592661938CEpreparation-assessments-v3.8.json
      /38/release_status
      Historical; current review incomplete
      H51-0E771D27DCA28A67F8819CA0preparation-assessments-v3.8.json
      /38/market_status/status
      Historical; current review incomplete
      H51-E330D75FF801AC855197FC9Fpreparation-assessments-v3.8.json
      /38/market_status/basis
      Historical; current review incomplete
      H51-E150FE7A669E60B3F382CB78preparation-assessments-v3.8.json
      /38/ten_point_assessment/exact_formulation
      Historical; current review incomplete
      H51-5BB8D91569ABCA81E6D683BEpreparation-assessments-v3.8.json
      /38/ten_point_assessment/reconstitution_concentration
      Historical; current review incomplete
      H51-217BD563C95AE9DCEF949A81preparation-assessments-v3.8.json
      /38/ten_point_assessment/maximum_or_recommended_final_concentration
      Historical; current review incomplete
      H51-69A659EC76AA76DE376BF63Bpreparation-assessments-v3.8.json
      /38/ten_point_assessment/appropriate_standardized_containers
      Historical; current review incomplete
      H51-35885E8746B1E68FAD91542Epreparation-assessments-v3.8.json
      /38/ten_point_assessment/adult_dosing_range
      Historical; current review incomplete
      H51-E6D76E118AA9CD295C7BA550preparation-assessments-v3.8.json
      /38/ten_point_assessment/pediatric_dosing_range
      Historical; current review incomplete
      H51-E52C7097F54414A9C147CFAEpreparation-assessments-v3.8.json
      /38/ten_point_assessment/neonatal_dosing_range
      Historical; current review incomplete
      H51-8A44C6A47F6596C483C7B33Cpreparation-assessments-v3.8.json
      /38/ten_point_assessment/infusion_time
      Historical; current review incomplete
      H51-B844D5315DFB3ED14A113D8Apreparation-assessments-v3.8.json
      /38/ten_point_assessment/fluid_restriction_alternatives
      Historical; current review incomplete
      H51-ED293752D88F110D5589917Bpreparation-assessments-v3.8.json
      /38/ten_point_assessment/current_manufacturer_labeling/setid
      Historical; current review incomplete
      H51-B10C14E4DE531F7C940D4CC8preparation-assessments-v3.8.json
      /38/ten_point_assessment/current_manufacturer_labeling/title
      Historical; current review incomplete
      H51-AAFB89766C0543D43300BCA6preparation-assessments-v3.8.json
      /38/ten_point_assessment/current_manufacturer_labeling/published_date
      Historical; current review incomplete
      H51-402F6B518D61FEE8E1EA5C9Apreparation-assessments-v3.8.json
      /38/ten_point_assessment/current_manufacturer_labeling/manufacturer
      Historical; current review incomplete
      H51-4D8C02342D44D4909E7544A6preparation-assessments-v3.8.json
      /38/ten_point_assessment/current_manufacturer_labeling/match_confidence
      Historical; current review incomplete
      H51-A94F53DA66EABC190ABE3B7Epreparation-assessments-v3.8.json
      /38/ten_point_assessment/current_manufacturer_labeling/url
      Historical; current review incomplete
      H51-51A4DF615CCC067980F964F5preparation-assessments-v3.8.json
      /38/field_provenance/exact_formulation/primary
      Historical; current review incomplete
      H51-7A16E69CECF1E1D12218D3D9preparation-assessments-v3.8.json
      /38/field_provenance/reconstitution_concentration/primary
      Historical; current review incomplete
      H51-348E0B841C480157251DF235preparation-assessments-v3.8.json
      /38/field_provenance/maximum_or_recommended_final_concentration/primary
      Historical; current review incomplete
      H51-BC64B58154F02B3CA79E8EFFpreparation-assessments-v3.8.json
      /38/field_provenance/appropriate_standardized_containers/primary
      Historical; current review incomplete
      H51-B1C5CD7457E22D3767C2E297preparation-assessments-v3.8.json
      /38/field_provenance/adult_dosing_range/primary
      Historical; current review incomplete
      H51-565EAF2F24BD97E93DEEBD3Epreparation-assessments-v3.8.json
      /38/field_provenance/pediatric_dosing_range/primary
      Historical; current review incomplete
      H51-651F923DBC1F8582238CB5A4preparation-assessments-v3.8.json
      /38/field_provenance/neonatal_dosing_range/primary
      Historical; current review incomplete
      H51-DD795E37BA3ABB47715D2871preparation-assessments-v3.8.json
      /38/field_provenance/infusion_time/primary
      Historical; current review incomplete
      H51-2F439C8E19E40249ADE580EApreparation-assessments-v3.8.json
      /38/field_provenance/fluid_restriction_alternatives/primary
      Historical; current review incomplete
      H51-3CDBF84C2804263DDE986DF0preparation-assessments-v3.8.json
      /38/field_provenance/current_manufacturer_labeling/primary
      Historical; current review incomplete
      H51-D5187CDEA7B80F0A8996E807preparation-assessments-v3.8.json
      /38/population_applicability/adult/applicability
      Historical; current review incomplete
      H51-D6F1F01AC9666C49FE0C9DB0preparation-assessments-v3.8.json
      /38/population_applicability/adult/guide_generation_allowed
      Historical; current review incomplete
      H51-9EFB0611BEE5A687016CDDA4preparation-assessments-v3.8.json
      /38/population_applicability/pediatric/applicability
      Historical; current review incomplete
      H51-EA4105CE41CBDD7843B79513preparation-assessments-v3.8.json
      /38/population_applicability/pediatric/guide_generation_allowed
      Historical; current review incomplete
      H51-502CA456B44DBC27FB55E3D9preparation-assessments-v3.8.json
      /38/population_applicability/neonatal/applicability
      Historical; current review incomplete
      H51-51D05898C900C99D628D2030preparation-assessments-v3.8.json
      /38/population_applicability/neonatal/guide_generation_allowed
      Historical; current review incomplete
      H51-D3812B8730B9A2839D345130preparation-assessments-v3.8.json
      /38/route_presence/structured_dilution
      Historical; current review incomplete
      H51-D3220CB10B739AF5E74A2F39preparation-assessments-v3.8.json
      /38/route_presence/iv_push
      Historical; current review incomplete
      H51-1C7A65BD5EA7BED0134515F4preparation-assessments-v3.8.json
      /38/route_presence/continuous_infusion
      Historical; current review incomplete
      H51-5FC26B6C6CAA6BE809DAD4FCpreparation-assessments-v3.8.json
      /38/route_presence/pediatric_source
      Historical; current review incomplete
      H51-4BDDAE3DA7590D9DADD0E3BFpreparation-assessments-v3.8.json
      /38/route_presence/neonatal_source
      Historical; current review incomplete
      H51-7BD77A44C9AD934AEB5F1321preparation-assessments-v3.8.json
      /38/legacy_reference/status
      Historical; current review incomplete
      H51-D6159B380B0F81B68A686E05preparation-assessments-v3.8.json
      /38/label_resolution/status
      Historical; current review incomplete
      H51-A79A7D6C7417F66116A64921preparation-assessments-v3.8.json
      /38/source_files/0
      Historical; current review incomplete
      H51-B1B21B40C065C3EB26BC928Dpreparation-assessments-v3.8.json
      /38/source_files/1
      Historical; current review incomplete
      H51-DA264B90EA2978D822BF37AApreparation-assessments-v3.8.json
      /38/source_files/2
      Historical; current review incomplete
      H51-06B817B18691490AFE4FB85Bpreparation-assessments-v3.8.json
      /38/clinical_release_note
      Historical; current review incomplete